GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3SBio, Inc. (FRA:YFK) » Definitions » EBIT

3SBio, (FRA:YFK) EBIT : €135.9 Mil (TTM As of Dec. 2016)


View and export this data going back to . Start your Free Trial

What is 3SBio, EBIT?

3SBio,'s earnings before interest and taxes (EBIT) for the six months ended in Dec. 2016 was €78.2 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2016 was €135.9 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. 3SBio,'s annualized ROC % for the quarter that ended in Dec. 2016 was 9.12%. 3SBio,'s annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2016 was 41.40%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. 3SBio,'s Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2016 was 24.42%.


3SBio, EBIT Historical Data

The historical data trend for 3SBio,'s EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3SBio, EBIT Chart

3SBio, Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec14 Dec15 Dec16
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.56 15.75 51.03 87.46 136.69

3SBio, Semi-Annual Data
Jun06 Dec06 Jun07 Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.93 43.09 44.74 57.68 78.19

Competitive Comparison of 3SBio,'s EBIT

For the Biotechnology subindustry, 3SBio,'s EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


3SBio,'s EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 3SBio,'s EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where 3SBio,'s EV-to-EBIT falls into.



3SBio, EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2016 adds up the semi-annually data reported by the company within the most recent 12 months, which was €135.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


3SBio,  (FRA:YFK) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

3SBio,'s annualized ROC % for the quarter that ended in Dec. 2016 is calculated as:

ROC % (Q: Dec. 2016 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2016 ) + Invested Capital (Q: Dec. 2016 ))/ count )
=136.654 * ( 1 - 14.72% )/( (1268.667 + 1287.273)/ 2 )
=116.5385312/1277.97
=9.12 %

where

Invested Capital(Q: Jun. 2016 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1470.145 - 75.817 - ( 125.661 - max(0, 184.099 - 364.693+125.661))
=1268.667

Invested Capital(Q: Dec. 2016 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1512.296 - 82.218 - ( 142.805 - max(0, 156.674 - 306.976+142.805))
=1287.273

Note: The Operating Income data used here is two times the semi-annual (Dec. 2016) data.

2. Joel Greenblatt's definition of Return on Capital:

3SBio,'s annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2016 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2016 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2016  Q: Dec. 2016
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=156.378/( ( (275.356 + max(160.06, 0)) + (241.502 + max(78.525, 0)) )/ 2 )
=156.378/( ( 435.416 + 320.027 )/ 2 )
=156.378/377.7215
=41.40 %

where Working Capital is:

Working Capital(Q: Jun. 2016 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 35.168 + 203.864) - (75.817 + 0 + 3.155)
=160.06

Working Capital(Q: Dec. 2016 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(107.618 + 35.954 + 20.599) - (82.218 + 0 + 3.428)
=78.525

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2016) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

3SBio,'s Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2016 )
=135.871/556.286
=24.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


3SBio, EBIT Related Terms

Thank you for viewing the detailed overview of 3SBio,'s EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


3SBio, (FRA:YFK) Business Description

Traded in Other Exchanges
N/A
Address
3SBio Inc is engaged in the healthcare sector based in China. It is a pharmaceutical products company and its core activities pertain to developing, manufacturing and marketing biopharmaceuticals. Its portfolio of products comprises of TPIAO and Yisaipu. TPIAO is the only commercialized recombinant human thrombopoietin (rhTPO) product in the world and Yisaipu is a TNF inhibibator product and accounts for the major share in the pharmaceutical industry in China. Most of the company's activities are focused on China while having a minor footprint in a foreign land.

3SBio, (FRA:YFK) Headlines

No Headlines